[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353615-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353615-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","anti-csf-1r-therapy-with-combined-immuno-chemotherapy-coordinate-an-adaptive-immune-response-to-eliminate-macrophage-enriched-triple-negative-breast-cancers","Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers","","Metastatic triple negative breast cancer (mTNBC) has limited therapeutic options and high mortality, with cold tumor immune microenvironments marked by low T cells and high tumor-associated macrophages (TAMs). A combined regimen using low-dose cyclophosphamide and anti-CSF-1R antibody together with anti-PD-1 shows strong efficacy in aggressive Trp53 null models featuring macrophage infiltration. Mechanistically, CSF-1R inhibition plus cyclophosphamide disrupts the M-CSF/CSF-1R axis, elevating IL-17, IL-5, type II interferon, and increases B- and T-cell infiltration. An anti-PD-1 maintenance dose mitigates de novo PD-L1 intra-tumoral heterogeneity linked to recurrence.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/anti-csf-1r-therapy-with-combined-immuno-chemotherapy-coordinate-an-adaptive-immune-response-to-eliminate-macrophage-enriched-triple-negative-breast-cancers/353615/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/anti-csf-1r-therapy-with-combined-immuno-chemotherapy-coordinate-an-adaptive-immune-response-to-eliminate-macrophage-enriched-triple-negative-breast-cancers/353615.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is metastatic triple negative breast cancer difficult to treat?","Question",{"text":63,"@type":64},"mTNBC often has limited options, tends to develop resistance, and is associated with high mortality. A cold tumor immune microenvironment with low T cells and high TAMs is linked to failure of standard chemotherapy and immune checkpoint blockade.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What combined treatment is described to target the macrophage-enriched immune environment?",{"text":68,"@type":64},"The regimen combines low-dose cyclophosphamide with anti-CSF-1R targeted therapy (SNDX-ms6352) and anti-PD-1. It is reported as highly effective in aggressive metastatic Trp53 null TNBC transplantable syngeneic models with high macrophage infiltration.",{"name":70,"@type":61,"acceptedAnswer":71},"How does CSF-1R inhibition plus cyclophosphamide change the tumor immune response?",{"text":72,"@type":64},"The approach disrupts the M-CSF/CSF-1R axis, upregulating IL-17, IL-5, and type II interferon, leading to elevated B- and T-cell infiltration. A maintenance anti-PD-1 dose helps address de novo PD-L1 intra-tumoral heterogeneity associated with recurrence.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353615,1790180415,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104,"preview_page_count":33,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Article [https://doi.org/10.1038/s41467-025-67964-2](https://doi.org/10.1038/s41467-025-67964-2)  \nAnti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers  \nReceived: 30 April 2025  \n\n| Accepted: 12 December 2025 |\n| --- |\n| |\n| Check for updates |\n\nDiego A. Pedroza 1,2,3, Xueying Yuan1,4, Fengshuo Liu 1,2,3,4,  \nHilda L. Chan 1,2,3,5, Christina Zhang1, William Bowie2,6, Alex J. Smith1,4, Sebastian J. Calderon1, Nadia Lieu1, Weiguo Wu7, Paul Porter7, Poonam Sarkar8, Na Zhao 1,3, Constanze V. Oehler 1, Ondrej Peller 1, M. Waleed Gaber8, Qian Zhu 2,3,6, Charles M. Perou9, Xiang H-F. Zhang 1,2,3,10 &  \nJeffrey M. Rosen 1,3   \nWomen diagnosed with metastatic triple negative breast cancer(mTNBC)have limited treatment options, are more prone to develop resistance and are associated with high mortality. A cold tumor immune microenvironment (TIME) characterized by low T cells and high tumor associated macrophages (TAMs) in mTNBC is associated with the failure of standard-of-care chemotherapy and immune checkpoint blockade (ICB) treatment. We demonstrate that the combination of immunomodulatory low-dose Cyclophosphamide (CTX) coupled with anti-CSF-1R antibody targeted therapy (SNDX-ms6352) and anti-PD-1 (ICB), was highly effective against aggressive metastatic Trp53 null TNBC transplantable syngeneic models that present with high macrophage inﬁltration. Mechanistically, CSF-1R inhibition along with CTX disrupted the M-CSF/CSF-1R axis which upregulated IL-17, IL-5 and type II interferon resulting in elevated B-and T cell inﬁltration. Addition of an anti-PD- 1 maintenance dose helped overcome de novo PD-L1 intra-tumoral heterogeneity (ITH) associated recurrence in lung and liver mTNBC.  \nTriple negative breast cancer (TNBC) is the most aggressive breast cancer with an overall poorer prognosis compared to other breast cancer subtypes1. Newly approved immune checkpoint blockade (ICB) accompanied by cytotoxic chemotherapies can now be administered to TNBC patients2. While multiple clinical trials have reported positive outcomes for TNBC including those utilizing these T cell activating agents3,4 the response rates in these patients vary and clearly more reﬁned therapies are needed to improve patient survival especially in  \nthe metastatic setting. The Tumor Immune Microenvironment (TIME) in TNBC has been suggested to play a critical role in patient response. Tumor plasticity and the Epithelial-to-Mesenchymal Transition (EMT)5 are critical for metastasis and a relationship exists between EMT and myeloid cells, particularly Tumor Associated Macrophages (TAMs)6. Results from the ARTEMIS (NCT02276443) clinical trial show that TNBC patients with a high EMT/macrophage score failed to undergo a pathological Complete Response (pCR) following neoadjuvant  \nA full list of afﬁliations appears at the end of the paper. [e-mail:](e-mail: jrosen@bcm.edu)[ jrosen@bcm.edu](e-mail: jrosen@bcm.edu)  \nchemotherapy (NACT)7,8. Furthermore, the clinical beneﬁt of Immune Checkpoint Blockade (ICB) is modest and poor patient outcomes maybe due in part to the presence of immunosuppressive macrophages within the TIME.  \nMost patients die from metastatic disease and as such metastatic breast cancer remains fatal for 97−99% of those diagnosed with a median survival of only 18−24 months9. In the recently published AURORA trials, proﬁling of paired TNBC patient samples from the primary and metastatic site have shown an immunologically quiescent TIME in sites of metastasis as compared to the primary site, with the liver having the coldest TIME. Pathway analysis done on these samples have shown a downregulation ofT-and B cell receptor signaling in the metastatic sites accompanied by an abundance of macrophages and neutrophils10,11. Several strategies have been deployed to therapeutically manipulate TAMs within TNBCs. These include macrophage reprogramming, using Class II HDA","cbCainCS3Nd4vJ1o","https://ap.wps.com/l/cbCainCS3Nd4vJ1o","pdf",9908263,"English","# Background\n## Cold tumor immune microenvironment in mTNBC\n# Combined therapy strategy\n## Low-dose cyclophosphamide and anti-CSF-1R with anti-PD-1\n# Mechanistic effects\n## Disruption of M-CSF/CSF-1R axis and cytokine upregulation\n# Overcoming immune resistance\n## Maintenance anti-PD-1 and PD-L1 intra-tumoral heterogeneity\n# Prior work and rationale\n## Limits of prior CSF-1R inhibition approaches","[{\"question\":\"Why is metastatic triple negative breast cancer difficult to treat?\",\"answer\":\"mTNBC often has limited options, tends to develop resistance, and is associated with high mortality. A cold tumor immune microenvironment with low T cells and high TAMs is linked to failure of standard chemotherapy and immune checkpoint blockade.\"},{\"question\":\"What combined treatment is described to target the macrophage-enriched immune environment?\",\"answer\":\"The regimen combines low-dose cyclophosphamide with anti-CSF-1R targeted therapy (SNDX-ms6352) and anti-PD-1. It is reported as highly effective in aggressive metastatic Trp53 null TNBC transplantable syngeneic models with high macrophage infiltration.\"},{\"question\":\"How does CSF-1R inhibition plus cyclophosphamide change the tumor immune response?\",\"answer\":\"The approach disrupts the M-CSF/CSF-1R axis, upregulating IL-17, IL-5, and type II interferon, leading to elevated B- and T-cell infiltration. A maintenance anti-PD-1 dose helps address de novo PD-L1 intra-tumoral heterogeneity associated with recurrence.\"}]","Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers | PDF",1790106362,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/521319595f0d50143ecdc276eccf5509.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6efe6ac834a1ddae8b3b0c5214e6629.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff54fc794a29991501a7d952a330c5bf.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a7733e37a1f17b53eb628f6d3c96d16.webp",980,1301]